Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RGNX
stocks logo

RGNX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
61.72M
+190.92%
-0.638
-36.85%
77.53M
-12.9%
-0.316
-363.33%
52.26M
+144.7%
-0.870
-36.96%
Estimates Revision
The market is revising Downward the revenue expectations for REGENXBIO Inc. (RGNX) for FY2025, with the revenue forecasts being adjusted by -14.1% over the past three months. During the same period, the stock price has changed by 33.68%.
Revenue Estimates for FY2025
Revise Downward
down Image
-14.1%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+14.76%
In Past 3 Month
Stock Price
Go Up
up Image
+33.68%
In Past 3 Month
Wall Street analysts forecast RGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGNX is 24.25 USD with a low forecast of 14.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast RGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGNX is 24.25 USD with a low forecast of 14.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 12.980
sliders
Low
14.00
Averages
24.25
High
37.00
Current: 12.980
sliders
Low
14.00
Averages
24.25
High
37.00
Morgan Stanley
NULL -> Overweight
maintain
$24 -> $25
2025-11-07
Reason
Morgan Stanley
Price Target
$24 -> $25
2025-11-07
maintain
NULL -> Overweight
Reason
Morgan Stanley raised the firm's price target on Regenxbio to $25 from $24 and keeps an Overweight rating on the shares.
Leerink
Mani Foroohar
Outperform
maintain
2025-08-19
Reason
Leerink
Mani Foroohar
Price Target
2025-08-19
maintain
Outperform
Reason
Leerink analyst Mani Foroohar keeps an Outperform rating on Regenxbio after the company announced the FDA extended its review of clemidsogene lanparvovec for mucopolysaccharidosis II to February 8, 2026, from November 9, 2025. The extension follows submission of longer-term data for all patients in the pivotal study at the FDA's request, the analyst tells investors in a research note. Leerink believes the extension is related as much to the recent turnover at the Center for Biologics Evaluation and Research than it is to specific review issues for Regenxbio. It says the delay is "not a needle mover" and should have a muted impact on the shares.
Barclays
Gena Wang
Overweight
downgrade
$50 -> $37
2025-08-08
Reason
Barclays
Gena Wang
Price Target
$50 -> $37
2025-08-08
downgrade
Overweight
Reason
Barclays analyst Gena Wang lowered the firm's price target on Regenxbio to $37 from $50 and keeps an Overweight rating on the shares following the Q2 report.
RBC Capital
Outperform
to
NULL
downgrade
$21 -> $17
2025-08-08
Reason
RBC Capital
Price Target
$21 -> $17
2025-08-08
downgrade
Outperform
to
NULL
Reason
RBC Capital lowered the firm's price target on Regenxbio to $17 from $21 and keeps an Outperform rating on the shares after its Q2 results. In DMD, the company's pivotal trial that may lead to accelerated approval is ongoing, the analyst tells investors in a research note. RBC adds that it continues to like the setup given an undemanding valuation.
Goldman Sachs
Paul Choi
Hold
Maintains
$14 → $12
2025-04-17
Reason
Goldman Sachs
Paul Choi
Price Target
$14 → $12
2025-04-17
Maintains
Hold
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$34
2025-03-21
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$34
2025-03-21
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Regenxbio Inc (RGNX.O) is -4.73, compared to its 5-year average forward P/E of 2.86. For a more detailed relative valuation and DCF analysis to assess Regenxbio Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
2.86
Current PE
-4.73
Overvalued PE
23.41
Undervalued PE
-17.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
6.45
Undervalued EV/EBITDA
-13.79

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.94
Current PS
0.00
Overvalued PS
9.41
Undervalued PS
2.47
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

RGNX News & Events

Events Timeline

(ET)
2025-11-06
07:12:11
Regenxbio anticipates cash and equivalents will support operations through early 2027.
select
2025-11-06
07:11:15
Regenxbio Announces Q3 EPS of $1.20, Below Consensus Estimate of $1.30
select
2025-11-03 (ET)
2025-11-03
10:28:44
Stifel: FDA's reversal on uniQure is not expected to affect Regenxbio's initiatives.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11-27SeekingAlpha
Regenxbio submits $300M mixed shelf registration statement

  • Shelf Registration Filing: Regenxbio (RGNX) has filed a shelf registration to offer up to $300 million in various securities, including common stock, preferred stock, and debt securities.

  • Pipeline Developments: The company is advancing its late-stage pipeline, with plans to release top-line data for RGX-202 in Duchenne muscular dystrophy in early Q2 2026 and aims for a commercial launch in 2027.

[object Object]
Preview
1.0
11-25PRnewswire
REGENXBIO to Participate in Upcoming Investor Conference

  • Investor Conference Participation: REGENXBIO Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference with a fireside chat scheduled for December 2 at 8:30 a.m. ET in New York, NY.

  • Webcast Availability: A live webcast of the fireside chat will be accessible on REGENXBIO's website, with an archived replay available for approximately 30 days post-event.

  • Company Overview: REGENXBIO is a biotechnology company focused on gene therapy, with a late-stage pipeline targeting rare and retinal diseases, including treatments for Duchenne and MPS I and II.

  • Impact of Gene Therapies: The company's AAV gene therapy platform has treated thousands of patients and aims to transform healthcare delivery for millions through its investigational therapies.

[object Object]
Preview
9.5
11-09Yahoo Finance
Earnings Report: REGENXBIO Inc. (NASDAQ:RGNX) Releases Results, Analysts Raise Their Projections

  • Quarterly Results Overview: REGENXBIO Inc. reported revenues of US$30 million, exceeding estimates by 22%, but also posted a statutory loss of US$1.20 per share, which was less than analysts had anticipated.

  • Analyst Forecast Updates: Following the earnings report, analysts have revised their revenue forecasts for 2026 to US$274.4 million, a 70% increase from the previous year, while also reducing the expected loss per share to US$1.67.

  • Price Target Insights: The consensus price target for REGENXBIO remains unchanged at US$29.55, indicating analysts' concerns about ongoing losses despite improved revenue outlooks, with a wide range of individual price targets from US$14.00 to US$52.00.

  • Growth Comparison: REGENXBIO is expected to grow its revenues at an annualized rate of 53% through 2026, significantly outpacing its historical decline and exceeding the 21% growth forecast for other companies in the industry.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Regenxbio Inc (RGNX) stock price today?

The current price of RGNX is 12.98 USD — it has increased 0.78 % in the last trading day.

arrow icon

What is Regenxbio Inc (RGNX)'s business?

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

arrow icon

What is the price predicton of RGNX Stock?

Wall Street analysts forecast RGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGNX is 24.25 USD with a low forecast of 14.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Regenxbio Inc (RGNX)'s revenue for the last quarter?

Regenxbio Inc revenue for the last quarter amounts to 29.73M USD, increased 22.88 % YoY.

arrow icon

What is Regenxbio Inc (RGNX)'s earnings per share (EPS) for the last quarter?

Regenxbio Inc. EPS for the last quarter amounts to -1.20 USD, increased 2.56 % YoY.

arrow icon

What changes have occurred in the market's expectations for Regenxbio Inc (RGNX)'s fundamentals?

The market is revising Downward the revenue expectations for REGENXBIO Inc. (RGNX) for FY2025, with the revenue forecasts being adjusted by -14.1% over the past three months. During the same period, the stock price has changed by 33.68%.
arrow icon

How many employees does Regenxbio Inc (RGNX). have?

Regenxbio Inc (RGNX) has 353 emplpoyees as of December 05 2025.

arrow icon

What is Regenxbio Inc (RGNX) market cap?

Today RGNX has the market capitalization of 657.09M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free